“Preclinical and clinical data suggest that cannabidiol (CBD), a major non-psychotomimetic compound from Cannabis sativa, induces antipsychotic-like effects…
These results indicate that repeated treatment with CBD, similar to clozapine, reverses the psychotomimetic-like effects and attenuates molecular changes observed after chronic administration of an NMDAR antagonist.
These data support the view that CBD may have antipsychotic properties.” http://www.ncbi.nlm.nih.gov/pubmed/25618402
“Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug… a controlled clinical trial comparing CBD with an atypical antipsychotic drug have confirmed that this cannabinoid can be a safe and well-tolerated alternative treatment for schizophrenia.” http://www.ncbi.nlm.nih.gov/pubmed/16612464
“A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation… These results support the idea that CBD may be a future therapeutic option in psychosis, in general and in schizophrenia, in particular.” http://www.ncbi.nlm.nih.gov/pubmed/22716160